Zobrazit minimální záznam

Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers

dc.contributor.authorHemminki, Kari Jussi
dc.contributor.authorSundquist, Kristina
dc.contributor.authorSundquist, Jan
dc.contributor.authorFoersti, Asta
dc.contributor.authorLiška, Václav
dc.contributor.authorHemminki, Akseli
dc.contributor.authorLi, Xinjun
dc.date.accessioned2023-12-12T10:11:07Z
dc.date.available2023-12-12T10:11:07Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2111
dc.description.abstractSimple Summary Liver cancer is often used as a general term for cancers of the liver (hepatocellular carcinoma, HCC), the gallbladder, and the bile ducts. The well-known risk factors are alcohol and viral hepatitis, but these are risk factors of mainly HCC. For gallbladder cancer, gallstones are important risk factors, and for bile ducts, infections in the ducts are important. For all these cancers, autoimmune diseases and diabetes increase risk. This study shows that these risk factors, in combination, explain 50% or more of the causes of these cancers. The novelty of the present study was the use of national Swedish hospital records for potential risk factors (comorbidities) of hepatobiliary cancers and the estimation of subsequent risks of hepatobiliary cancers in these patients. The underlying mechanism for these cancers is a chronic infection which should be considered a marker of disease progression and a possible target for intervention. Background: We aim to estimate population-attributable fractions (PAF) for 13 comorbidities potentially predisposing to hepatobiliary cancer of hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cancers of the intrahepatic and extrahepatic bile ducts (ICC and ECC), and ampullary cancer. Methods: Patients were identified from the Swedish Inpatient Register from 1987 to 2018 and cancers from the Swedish Cancer Registry from 1997 through 2018. PAFs were calculated for each comorbidity-associated cancer using a cohort study design. Results: For male HCC, the major individual comorbidities (PAF > 10) were diabetes, alcohol-related liver disease, and hepatitis C virus infection. For female HCC, diabetes and autoimmune diseases were important contributors. For female GBC, gallstone disease was an overwhelming contributor, with a PAF of 30.57%, which was also important for men. The overall PAF for male ICC was almost two times higher than the female one. For ECC and ampullary cancer, infection of bile ducts was associated with the highest PAF. Conclusions: The 13 comorbidities accounted for 50% or more of the potential etiological pathways of each hepatobiliary cancer except female ICC. The underlying convergent mechanism for these cancers may be chronic inflammation lasting for decades and thus offering possibilities for intervention and disease monitoring.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.3390/cancers15123092
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titlePopulation-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancersen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-12-12T10:11:07Z
dc.subject.keywordhepatocellular carcinomaen
dc.subject.keywordcomorbidityen
dc.subject.keywordrisk factoren
dc.subject.keywordbile duct infectionen
dc.subject.keywordalcoholen
dc.subject.keywordviral infectionen
dc.subject.keyworden
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/FN/I-FN/I-FNP-04
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/EU/FP8/856620
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.date.embargoStartDate2023-12-12
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.3390/cancers15123092
dc.identifier.utWos001017091000001
dc.identifier.eidScopus2-s2.0-85164028792
dc.identifier.obd633379
dc.identifier.pubmed37370702
dc.subject.rivPrimary30000::30200::30204
dcterms.isPartOf.nameCancers
dcterms.isPartOf.issn2072-6694
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume15
dcterms.isPartOf.journalIssue12
uk.faculty.primaryId111
uk.faculty.primaryNameLékařská fakulta v Plznics
uk.faculty.primaryNameFaculty of Medicine in Pilsenen
uk.faculty.secondaryId54
uk.faculty.secondaryNameFakultní nemocnice Plzeňcs
uk.faculty.secondaryNameUniversity Hospital in Pilsenen
uk.department.primaryId100012968318
uk.department.primaryNameBiomedicínské centrumcs
uk.department.primaryNameBiomedical Centeren
uk.department.secondaryId1399
uk.department.secondaryId5000002701
uk.department.secondaryNameChirurgická klinikacs
uk.department.secondaryNameDepartment of Surgeryen
uk.department.secondaryNameChirurgická klinikacs
uk.department.secondaryNameDepartment of Surgeryen
dc.description.pageRangenestránkováno
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitlePopulation-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancersen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam